Revumenib became the first FDA-approved menin inhibitor based on results from the AUGMENT-101 study, which demonstrated an overall response rate of 68% in heavily pretreated KMT2A-rearranged acute leukemia patients [31]. Here, KMT2A is linked to acute leukemia.